Membership Directory
Inotek Pharmaceuticals Corporation
Category: Drug Development
Phone: + (781) 676-2122
Fax: + (781) 676-2155
Website: http://www.inotekcorp.com
Location: Lexington, MA
Inotek is a clinical-stage pharmaceutical company developing therapies with novel mechanisms of action to address significant diseases of the eye. Inotek's lead program, INO-8875, has completed a Phase 1/2 trial in glaucoma patients. INO-8875 was well tolerated and showed a statistically significant reduction in intraocular pressure (IOP). INO-8875 represents a new mechanism to treat glaucoma by targeting the trabecular meshwork, the main pathway used by healthy eyes to maintain normal IOP. Inotek has also been a leader in poly (ADP ribose) polymerase (PARP) inhibitor research and has a portfolio of superoxide dismutase (SOD) mimetics. Both PARP and SOD are attractive targets for the treatment of retinal disease, and Inotek believes its PARP inhibitors and SOD mimetic compounds hold great potential in agerelated macular degeneration and other ophthalmic indications. Inotek has built a first-class drug development and management team to advance its programs. Inotek is privately held and based in Lexington, MA.
Back to list